Noninvasive Saliva-based <i>EGFR</i> Gene Mutation Detection in Patients with Lung Cancer

Fang, Wei; Lin, Chien‐Chung; Joon, Aron Y.; Feng, Ziding; Troche, Gabriel E.; Lira, Maruja E.; Chia, David; Mao, Mao; Ho, Chung Liang; Su, Wu Chou; Wong, David T.

doi:10.1164/rccm.201406-1003oc

Cited by 154 publications

(164 citation statements)

References 41 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…195 However, a new technique was developed at the University of California at Los Angeles (UCLA), School of Dentistry, called EFIRM. 196 This technique enables disrupting and releasing the contents from exosomes and on-site monitoring of the released exosomal RNA/proteins biomarkers for a specific cancer. The first step involves pipetting of a sample of biofluid to the surface of a biosensor and applying a pulsed electric field to release molecular content from the exosome.…”

Section: Liquid Biopsymentioning

confidence: 99%

“…197 This technique allows direct detection in plasma and in saliva of specific mutations present in cancers, i.e. detection of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC), thus eliminating the need for quantitative PCR 196 ( Figure 4). The results of performed experiments demonstrate that tumor-shed exosomes can be detected not only in blood, but also in saliva, thus launching a new venue for the non-invasive detection of tumor-specific proteins, micro RNAs, mRNAs, as well as gene mutations in saliva.…”

Section: Liquid Biopsymentioning

confidence: 99%

See 1 more Smart Citation

Saliva diagnostics – Current views and directions

Kaczor‐Urbanowicz

Carreras‐Presas

Aro

et al. 2016

Exp Biol Med (Maywood)

327

271

View full text Add to dashboard Cite

The purpose of this mini-review is to make an update about the present and future applications of saliva as a diagnostic biofluid in many fields of science such as dentistry, medicine and pharmacotherapy. Using saliva as a fluid for diagnostic purposes would be a huge breakthrough for both patients and healthcare providers since saliva collection is easy, non-invasive and inexpensive. We will go through the current main diagnostic applications of saliva, and provide a highlight on the emerging, newly developing technologies and tools for cancer screening, detection and monitoring. AbstractIn this review, we provide an update on the current and future applications of saliva for diagnostic purposes. There are many advantages of using saliva as a biofluid. Its collection is fast, easy, inexpensive, and non-invasive. In addition, saliva, as a ''mirror of the body,'' can reflect the physiological and pathological state of the body. Therefore, it serves as a diagnostic and monitoring tool in many fields of science such as medicine, dentistry, and pharmacotherapy. Introduced in 2008, the term ''Salivaomics'' aimed to highlight the rapid development of knowledge about various ''omics'' constituents of saliva, including: proteome, transcriptome, micro-RNA, metabolome, and microbiome. In the last few years, researchers have developed new technologies and validated a wide range of salivary biomarkers that will soon make the use of saliva a clinical reality. However, a great need still exists for convenient and accurate point-of-care devices that can serve as a non-invasive diagnostic tool. In addition, there is an urgent need to decipher the scientific rationale and mechanisms that convey systemic diseases to saliva. Another promising technology called liquid biopsy enables detection of circulating tumor cells (CTCs) and fragments of tumor DNA in saliva, thus enabling non-invasive early detection of various cancers. The newly developed technology-electric field-induced release and measurement (EFIRM) provides near perfect detection of actionable mutations in lung cancer patients. These recent advances widened the salivary diagnostic approach from the oral cavity to the whole physiological system, and thus point towards a promising future of salivary diagnostics for personalized individual medicine applications including clinical decisions and post-treatment outcome predictions.

show abstract

Section: Liquid Biopsymentioning

confidence: 99%

Section: Liquid Biopsymentioning

confidence: 99%

Saliva diagnostics – Current views and directions

Kaczor‐Urbanowicz

Carreras‐Presas

Aro

et al. 2016

Exp Biol Med (Maywood)

327

271

View full text Add to dashboard Cite

show abstract

“…EGFR mutations in NSCLC patients have also been detected in saliva using electric field-induced release and measurement (EFIRM) with receiver operating characteristic analysis indicating that EFIRM detected exon 19 deletion with an area under the curve (AUC) of 0.94 and the L858R mutation with an AUC of 0.96 (53). However, this platform is not in widespread use clinically for the time being.…”

Section: Ctdna In Other Body Fluidsmentioning

confidence: 99%

Circulating DNA in EGFR-mutated lung cancer

Singh¹,

Li²,

Cheng³

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA) consists of short double stranded DNA fragments that are released by tumors including non-small cell lung cancer (NSCLC). With the identification of driver mutations in the epidermal growth factor receptor (EGFR) gene and development of targeted tyrosine kinase inhibitors (TKIs), the clinical outcome of NSCLC patients in this subgroup has improved tremendously.The gold standard to assess EGFR mutation is through tissue biopsy, which can be limited by difficulty in accessing the tumor, inability of patients to tolerate invasive procedures, insufficient sample for molecular testing and inability to capture intratumoral heterogeneity. The great need for rapid and accurate identification of activating EGFR mutations in NSCLC patients paves the road for ctDNA technology.Studies have demonstrated ctDNA to be a reliable complement to tumor genotyping. Platforms like digital polymerase chain reaction (PCR) and next-generation sequencing based analyses have made it possible to identify EGFR mutations in plasma with high sensitivity and specificity. This article will provide an overview on ctDNA in the context of EGFR mutated NSCLC, especially its emerging applications in diagnosis, disease surveillance, treatment monitoring and detection of resistance mechanisms.

show abstract

“…These include cerebrospinal fluid for neurological-related cancers[44], and saliva for lung cancers[105], among others. Given the stability limitations of ctNA, as described earlier, the sample handing procedures for these biological samples vary widely.…”

Section: Technologies For Capture Detection and Analysis Of Circulamentioning

confidence: 99%

Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis

Tadimety

Closson

et al. 2018

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Liquid biopsy, as a minimally invasive method of gleaning insight into the dynamics of diseases through a patient fluid sample, has been growing in popularity for cancer diagnosis, prognosis, and monitoring. While many technologies have been developed and validated in research laboratories, there has also been a push to expand these technologies into other clinical settings and as point of-care devices. In this review we discuss and evaluate microchip-based technologies for circulating tumor cell (CTC), exosome, and circulating tumor nucleic acid (ctNA) capture, detection, and analysis. Such integrated systems streamline otherwise multiple-step, manual operations to get a sample-to-answer quantitation. In addition, analysis of disease biomarkers is suited to point of care settings because of ease of use, low consumption of sample and reagents, and high throughput. We also cover the basics of biomarkers and their detection in biological fluid samples suitable for liquid biopsy on-chip. We focus on emerging technologies that process a small patient sample with high spatial-temporal resolution and derive clinically meaningful results through on-chip biomarker sensing and downstream molecular analysis in a simple workflow. This critical review is meant as a resource for those interested in developing technologies for capture, detection, and analysis platforms for liquid biopsy in a variety of settings.

show abstract

Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer

Cited by 154 publications

References 41 publications

Saliva diagnostics – Current views and directions

Saliva diagnostics – Current views and directions

Circulating DNA in EGFR-mutated lung cancer

Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis

Contact Info

Product

Resources

About